Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter derived from the amino acid tryptophan. It is the compound most often named when people talk about mood, depression, and the drugs used to treat them. Nearly every piece of that story carries myths alongside the facts: most of your serotonin is in your gut, not your brain; the two pools barely talk; and the "low serotonin causes depression" model that dominated pharma marketing for decades has never had strong empirical support. What is real is that serotonin participates in a remarkable number of systems, and drugs that affect it have real, if more modest and more complex, effects.
At a glance
What it does
In the gut, serotonin controls motility, secretion, and peristalsis. Enterochromaffin cells in the intestinal lining release serotonin in response to mechanical and chemical stimuli, and it coordinates the enteric nervous system's response — this is why drugs affecting serotonin so reliably produce nausea, constipation, or diarrhea as side effects. Platelets take up gut-derived serotonin and release it to support vasoconstriction and clotting at injury sites.
In the brain, serotonin originates from a small cluster of nuclei in the brainstem — primarily the raphe nuclei — that project axons throughout cortex, limbic system, and spinal cord. Central serotonin modulates mood, sleep architecture, appetite, pain processing, sexual function, impulse control, aggression, thermoregulation, and some aspects of memory and learning. It is not the "happy chemical" — it is a broadly modulatory signal that biases circuits toward specific behavioral states.
Peripheral and central serotonin pools are essentially independent. Serotonin does not cross the blood-brain barrier, so measuring blood serotonin tells you nothing about brain serotonin. The brain synthesizes its own from tryptophan that does cross the barrier. This is why you cannot meaningfully boost brain serotonin by eating serotonin-rich foods or by any supplement that does not itself cross.
How it works
Synthesis starts with tryptophan, an essential amino acid from diet. Tryptophan hydroxylase converts it to 5-hydroxytryptophan (5-HTP), which aromatic L-amino acid decarboxylase converts to serotonin. The rate-limiting step is tryptophan hydroxylase, which exists in two forms — TPH1 in peripheral tissues and TPH2 in the brain. TPH2 determines brain serotonin capacity; TPH1 handles gut and peripheral production.
Once synthesized and packaged into vesicles, serotonin is released at synapses or from enterochromaffin cells and cleared by the serotonin transporter (SERT) for reuptake. In the brain, MAO-A is the primary metabolizing enzyme, converting serotonin to 5-HIAA (5-hydroxyindoleacetic acid), which is excreted in urine. 5-HIAA measurement is used clinically to screen for carcinoid tumors — serotonin-secreting neuroendocrine tumors that can cause flushing, diarrhea, and cardiac valve disease.
Serotonin acts on at least 14 receptor subtypes across seven families (5-HT1 through 5-HT7), nearly all G-protein coupled except 5-HT3, which is a ligand-gated ion channel. This is an unusually wide receptor family, and different drugs acting on different subtypes produce wildly different clinical effects. 5-HT1A partial agonists (buspirone) treat anxiety. 5-HT1D/1B agonists (triptans) treat migraines by vasoconstricting cerebral vessels. 5-HT2A agonists are psychedelics (psilocybin, LSD). 5-HT2A antagonists help sleep and are part of atypical antipsychotics. 5-HT3 antagonists (ondansetron) prevent chemotherapy nausea. 5-HT4 agonists promote gut motility. All of these are "serotonergic" drugs.
SSRIs (selective serotonin reuptake inhibitors) block SERT, raising synaptic serotonin acutely. But clinical mood improvement takes weeks, not hours — inconsistent with a simple "more serotonin equals better mood" model. The current best understanding is that chronic SERT blockade triggers downstream changes in receptor sensitivity, neurogenesis, and circuit function, particularly in prefrontal and limbic regions. The acute neurochemical signature is not the therapeutic mechanism.
Levels & ranges
Central serotonin cannot be directly measured in living humans. Postmortem brain studies and CSF 5-HIAA measurements are the closest proxies, and both have significant limitations. Low CSF 5-HIAA correlates in some studies with impulsive aggression and suicide, but the relationship is noisy and not diagnostic.
Peripheral serotonin is measurable in blood (mostly platelet-bound) and has a normal range roughly 101-283 ng/mL whole blood, but this reflects gut and platelet pools, not brain activity. It is useful for diagnosing carcinoid syndrome (grossly elevated), not for routine psychiatric assessment. Direct-to-consumer "serotonin level" testing being marketed to the public is essentially meaningless for mood purposes.
24-hour urinary 5-HIAA is the standard screen for carcinoid tumors — normal is typically below 6-8 mg/24h; values above 25 mg/24h strongly suggest a secreting tumor. Dietary restriction is required for accuracy because bananas, pineapple, avocado, tomatoes, walnuts, and several other foods can falsely elevate the result.
When it goes wrong
The chemical imbalance theory of depression — that depression is caused by serotonin deficiency — shaped a generation of patient communication and drug marketing. A 2022 Moncrieff et al. umbrella review in Molecular Psychiatry examined the evidence and found that the serotonin hypothesis of depression does not have strong empirical support. Depressed patients do not reliably show lower serotonin on the available measures; tryptophan depletion does not reliably induce depression in healthy people; and the correlation between acute serotonin elevation from SSRIs and eventual mood improvement is weak.
This does not mean SSRIs do not work — they do, modestly and inconsistently, across populations. The network meta-analyses put the effect size in moderate-to-severe depression at clinically meaningful for responders and negligible for mild depression. It means that the simple "low serotonin → pill raises serotonin → depression fixed" narrative was always a marketing story, not a scientific model. The actual mechanism of SSRI benefit remains contested and probably involves downstream effects on neuroplasticity, circuit function, and receptor sensitivity — changes that play out over weeks, consistent with the clinical timeline.
Conditions with more direct serotonin pathology exist. Serotonin syndrome is an acute toxic state from excess serotonergic activity (usually from combining SSRIs with MAOIs, tramadol, certain stimulants, or MDMA), producing autonomic instability, hyperthermia, clonus, and in severe cases death. Carcinoid syndrome from serotonin-secreting neuroendocrine tumors produces flushing, diarrhea, and over years can cause right-sided cardiac valve disease from serotonin's effects on valve fibroblasts. Irritable bowel syndrome involves dysregulated gut serotonin signaling — explaining why 5-HT3 antagonists help IBS-D and 5-HT4 agonists help IBS-C.
SSRI-induced sexual dysfunction is extremely common (30-70% of users) and almost always underdiscussed in patient education. In a subset of patients it persists after discontinuation — post-SSRI sexual dysfunction (PSSD) — which has only recently been formally acknowledged by regulatory agencies. Emotional blunting ("I just don't care as much about anything") is another common and undercounted side effect that can present as treatment benefit when really it reflects blunted response to both negative and positive stimuli.
Interactions
Tryptophan availability to the brain matters at the margins. Tryptophan competes with several other amino acids (the large neutral amino acids) for the same blood-brain barrier transporter. After a carbohydrate meal, insulin shunts competing amino acids into muscle while sparing tryptophan, raising tryptophan's brain availability slightly. This is the mechanism behind the tryptophan-turkey-carbs-sleepy folk story — more urban legend than clinical effect, but the biochemistry underneath is real.
Exercise raises tryptophan uptake and serotonin turnover in the brain. Regular aerobic exercise has an effect size on depressive symptoms comparable to first-line antidepressants in meta-analyses of mild to moderate depression. Sunlight exposure and consistent morning light are reliably linked to improved mood through circadian effects that interact with serotonergic pathways.
Drug interactions that matter clinically: SSRIs with MAOIs or within two weeks of MAOI discontinuation is potentially lethal. SSRIs with tramadol, methadone, some triptans, linezolid, dextromethorphan, or MDMA can cause serotonin syndrome. Lithium augmentation of SSRIs is a standard treatment-resistant depression strategy but also raises serotonin syndrome risk. 5-HTP supplements can potentiate SSRIs. Psilocybin and LSD are serotonin 2A receptor partial agonists; the interaction with SSRIs is complex — chronic SSRIs blunt psychedelic response, while acute interaction can be unpredictable.
Psychedelic-assisted therapy using psilocybin and MDMA has produced substantial effects in treatment-resistant depression and PTSD in phase 2 and 3 trials. These are serotonergic interventions that work through fundamentally different mechanisms from SSRIs — acute receptor agonism paired with psychotherapy — and represent an emerging shift in serotonergic psychiatry.
Honest take
The "low serotonin causes depression" narrative was a pharmaceutical marketing triumph that outlived its scientific support by decades. SSRIs work for some people, moderately and inconsistently, through mechanisms that are still debated — not through correcting a deficiency of a neurotransmitter we can't even measure in living brains. If an SSRI is helping someone, that benefit is real and keeping it is legitimate. But if one has not worked after an adequate trial, or if side effects (especially sexual and emotional blunting) are making life worse, the honest read is that there is nothing "chemically imbalanced" about wanting to stop. Exercise, sleep regularity, morning light, and structured psychological therapy produce effect sizes in mild-to-moderate depression that rival SSRIs in meta-analyses, and the side effect profile is different. For treatment-resistant depression, psychedelic-assisted therapy and ketamine have produced real results the serotonergic drugs never did.
Sources
- Moncrieff et al., Molecular Psychiatry (2022) — umbrella review of the serotonin theory of depression and the gap between theory and evidence.
- Cipriani et al., The Lancet (2018) — comparative efficacy network meta-analysis of 21 antidepressants.
- Berger, Gray & Roth, Annual Review of Medicine — comprehensive review of serotonin receptor biology and therapeutic implications.
- Carhart-Harris et al., NEJM (2021) — psilocybin-assisted therapy versus escitalopram in depression, the key modern psychedelic trial.